The gut microbiota-SCFA-inflammation axis in patients with AECOPDOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This case-control study examined the gut microbiota-short-chain-fatty-acid-inflammation axis in acute exacerbation of chronic obstructive pulmonary disease. The hypothesis was that gut dysbiosis lowers SCFA and worsens inflammation. Gut microbiota were analyzed by 16S rDNA sequencing. SCFA were measured in stool by gas chromatography-mass spectrometry, and serum inflammatory factors were quantified by ELISA.
Who was studied?
The cohort was 24 patients with acute exacerbation of COPD and 18 healthy volunteers, recruited in China between January and May 2022. Mean age was 71 years in controls and 61 years in patients. Patients had reduced lung function, with lower FEV1 and FEV1/FVC, plus elevated white blood cells, neutrophils, and C-reactive protein. People on recent probiotics or antibiotics were excluded.
What were the most important findings?
Patients showed reduced gut microbiota richness and diversity, with lower Chao, Observed, ACE, and Shannon indices (all p below 0.05). Beta diversity differed significantly between groups. Controls were enriched in genera such as Paraprevotella, Parasutterella, and Romboutsia, while patients were enriched in Actinomyces, Mogibacterium, and Enterococcus. All six measured SCFA, including acetic, butyric, and propionic acid, were decreased in patients. Serum IL-6 was reduced in patients, while other inflammatory factors did not differ.
What are the greatest implications of this study?
The results support a gut microbiota-SCFA-inflammation axis during COPD exacerbations, with dysbiosis linked to lower SCFA production. Reduced SCFA-producing bacteria may explain the falling fatty acid levels. The unexpected drop in serum IL-6 may reflect inflammation being concentrated in the lungs rather than blood. The study is small and cross-sectional, without stable COPD patients, so causation cannot be established. Findings suggest gut bacteria may signal COPD progression.